TY - JOUR
AU - Chatelut,  Etienne
AB - Cancer Chemother Pharmacol (1999) 43: 520±521 Ó Springer-Verlag 1999 LETTER TO THE EDITORS Nathalie Perdaems á Nathalie Caunes Pierre Canal á Etienne Chatelut Received: 21 September 1998 / Accepted: 30 November 1998 Key words Etoposide á Pharmacokinetics á tection (i.e., 0.05 mg/l) at 72 h after the ®rst infusion. The P-glycoprotein á Intestinal elimination plasma area under the curve (AUC) of conjugated etoposide represented 12% of the total (conjugated plus unchanged etoposide) AUC. Table 1 shows the per- centages of the delivered dose recovered in bile and urine. The observed clearance of this patient coincides with the mean value previously reported (30.2 ml/min [2]). Numerous pharmacokinetics studies of etoposide have The plasma unbound fraction was twice that of the been performed during the last decade (see Joel [1] for review). However, the respective parts played by me- mean value observed in cancer patients (8.4% [2]). This was due more likely to her low plasma albumin level tabolism and biliary secretion in the nonrenal elimina- (i.e., 27 g/l) than to the high bilirubin level, since the tion pathways are not yet clear. A 75-year-old woman with a pancreatic neuroendo- bilirubin was mainly conjugated and does not bind to albumin in 
TI - Possible excretion of etoposide via the intestinal mucosa
JF - Cancer Chemotherapy and Pharmacology
DO - 10.1007/s002800050933
DA - 1999-03-01
UR - https://www.deepdyve.com/lp/springer-journals/possible-excretion-of-etoposide-via-the-intestinal-mucosa-wcYd9hnrdo
SP - 520
EP - 521
VL - 43
IS - 6
DP - DeepDyve
ER -